home / stock / san / san news


SAN News and Press, Banco Santander S.A. Sponsored ADR From 10/26/22

Stock Information

Company Name: Banco Santander S.A. Sponsored ADR
Stock Symbol: SAN
Market: NYSE
Website: santander.com

Menu

SAN SAN Quote SAN Short SAN News SAN Articles SAN Message Board
Get SAN Alerts

News, Short Squeeze, Breakout and More Instantly...

SAN - Banco Santander GAAP EPS of Euro0.137, Total income of Euro13.5B

Banco Santander press release ( NYSE: SAN ): Q3 GAAP EPS of €0.137. Total income of €13.5B (+13.2% Y/Y). The group continued to grow its customer base, adding eight million customers in the last twelve months, taking the total to 159 million. Th...

SAN - Buy BBVA For Its High-Dividend Yield Of 6.75%

Summary BBVA has strong fundamentals and has reported strong growth in recent quarters. While rising provisions are expected in the coming quarters, they aren’t a major threat for the bank’s capital return policy. BBVA offers an attractive dividend yield and an u...

SAN - Santander Bank Enhances Safety Net, Further Reduces Overdraft Fees for Every Client

Improvements include Eliminating Non-sufficient Funds Fee and Reduction of Overdraft Fee to $15 Santander Bank, N.A. ("Santander Bank,” “Santander” or “the Bank”) today announced further enhancements to Santander ® Safety Net...

SAN - Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old

Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old PR Newswire A majority of children on Dupixent (up to 68% on a higher dose) achiev...

SAN - Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes PR Newswire Sanofi US to co-promote teplizumab, adding it to its current commercial activities in diabetes care...

SAN - Banco Santander: Trading At Less Than 0.6 Times TBV And 5 Times Earnings

Summary Banco Santander is a Spanish bank, but generates most of its income from abroad. The share price has been sliding as recession fears are hitting the world economy. I still expect a full-year EPS north of 0.50 EUR, making the bank cheap. Introduction N...

SAN - Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis PR Newswire Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 7...

SAN - Santander US Issues Inaugural $500 Million Sustainability Notes Under Newly Released Sustainability Funding Global Framework

Santander Holdings USA, Inc. (“Santander US” and “Santander”) announced its first sustainable bond offering on Sept. 6. Santander US is the first Santander Group entity to issue bonds of this kind, utilizing Santander Group’s recently released Green, S...

SAN - Santander Bank Raises Its Prime Rate to 6.25%

Santander Bank, N.A. announced today it has raised its prime rate from 5.50% to 6.25%, effective September 21, 2022. Santander Bank, N.A. is one of the country’s largest retail and commercial banks with $102 billion in assets. With its corporate offices in Boston, the Ban...

SAN - Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet

Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet PR Newswire Dupixent is the first and only biologic that significantly improved skin clearance, and reduced itch and ...

Previous 10 Next 10